MBX Biosciences (MBX) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
MBX Biosciences (MBX) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 245.2% versus a loss of 18.4%. MBX Biosciences is the larger company by market cap ($2.63 billion vs $2.29 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBX | RXRX |
|---|---|---|
| Share price | $54.54 | $4.27 |
| Market cap | $2.63B | $2.29B |
| 1-day change | -4.18% | -7.78% |
| YTD return | +72.92% | +4.40% |
| 1-year return | +245.19% | -18.36% |
| 5-year return | — | -77.57% |
| EPS (TTM) | $-2.37 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $72.64 | $7.18 |
| 52-week low | $12.94 | $2.77 |
| Distance from 52-week high | -24.92% | -40.53% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +72.90% | +69.09% |
| Average volume | 556.72K | 20.28M |
| Shares outstanding | 48.16M | 535.34M |
| Employees | 63 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed RXRX by 263.5 percentage points over the past year.
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
MBX vs RXRX FAQ
Which is bigger, MBX Biosciences or Recursion Pharmaceuticals?
MBX Biosciences (MBX) is larger, with a market capitalization of $2.63B compared with $2.29B for Recursion Pharmaceuticals (RXRX).
Which stock has performed better over the past year, MBX or RXRX?
MBX returned +245.19% over the past 12 months, compared with -18.36% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are MBX Biosciences and Recursion Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for MBX Biosciences and Biotechnology: Biological Products (No Diagnostic Substances) for Recursion Pharmaceuticals.